Pharma & Healthcare
Global Carbapenem Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 607044
- Pages: 177
- Figures: 180
- Views: 1
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Carbapenem Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar S.p.A
Iterum Therapeutics plc (ITRM)
Daewoong Pharmaceutical
Aurobindo Pharma Ltd
Sumitomo Pharma
Pfizer Inc.
Segment by Type
Doripenem
Ertapenem
Imipenem
Meropenem
Panipenem
Biapenem
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Carbapenem Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Carbapenem Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar S.p.A
Iterum Therapeutics plc (ITRM)
Daewoong Pharmaceutical
Aurobindo Pharma Ltd
Sumitomo Pharma
Pfizer Inc.
Segment by Type
Doripenem
Ertapenem
Imipenem
Meropenem
Panipenem
Biapenem
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Carbapenem Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Carbapenem Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Carbapenem Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Doripenem
1.2.3 Ertapenem
1.2.4 Imipenem
1.2.5 Meropenem
1.2.6 Panipenem
1.2.7 Biapenem
1.3 Market Segmentation by Application
1.3.1 Global Carbapenem Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Carbapenem Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Carbapenem Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Carbapenem Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Carbapenem Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Carbapenem Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Carbapenem Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Doripenem Market Size by Manufacturers
3.5.2 Ertapenem Market Size by Manufacturers
3.5.3 Imipenem Market Size by Manufacturers
3.5.4 Meropenem Market Size by Manufacturers
3.5.5 Panipenem Market Size by Manufacturers
3.5.6 Biapenem Market Size by Manufacturers
3.6 Global Carbapenem Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Carbapenem Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Carbapenem Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Carbapenem Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Carbapenem Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Carbapenem Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Carbapenem Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Carbapenem Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Carbapenem Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Carbapenem Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Carbapenem Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Carbapenem Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Carbapenem Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Carbapenem Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Carbapenem Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Carbapenem Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Carbapenem Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Carbapenem Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Carbapenem Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Carbapenem Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Shandong New Era Pharmaceutical
11.1.1 Shandong New Era Pharmaceutical Corporation Information
11.1.2 Shandong New Era Pharmaceutical Business Overview
11.1.3 Shandong New Era Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.1.4 Shandong New Era Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.1.6 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.1.7 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.1.8 Shandong New Era Pharmaceutical Carbapenem Drugs SWOT Analysis
11.1.9 Shandong New Era Pharmaceutical Recent Developments
11.2 Shenzhen Haibin Pharmaceutical
11.2.1 Shenzhen Haibin Pharmaceutical Corporation Information
11.2.2 Shenzhen Haibin Pharmaceutical Business Overview
11.2.3 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.2.4 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.2.6 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.2.7 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.2.8 Shenzhen Haibin Pharmaceutical Carbapenem Drugs SWOT Analysis
11.2.9 Shenzhen Haibin Pharmaceutical Recent Developments
11.3 Sinopharm Guorui Pharmaceutical
11.3.1 Sinopharm Guorui Pharmaceutical Corporation Information
11.3.2 Sinopharm Guorui Pharmaceutical Business Overview
11.3.3 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.3.4 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.3.6 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.3.7 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.3.8 Sinopharm Guorui Pharmaceutical Carbapenem Drugs SWOT Analysis
11.3.9 Sinopharm Guorui Pharmaceutical Recent Developments
11.4 Taiwan Biotech Co., Ltd.
11.4.1 Taiwan Biotech Co., Ltd. Corporation Information
11.4.2 Taiwan Biotech Co., Ltd. Business Overview
11.4.3 Taiwan Biotech Co., Ltd. Carbapenem Drugs Product Models, Descriptions and Specifications
11.4.4 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Product in 2024
11.4.6 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Application in 2024
11.4.7 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Geographic Area in 2024
11.4.8 Taiwan Biotech Co., Ltd. Carbapenem Drugs SWOT Analysis
11.4.9 Taiwan Biotech Co., Ltd. Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Carbapenem Drugs Product Models, Descriptions and Specifications
11.5.4 Merck Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Merck Carbapenem Drugs Sales by Product in 2024
11.5.6 Merck Carbapenem Drugs Sales by Application in 2024
11.5.7 Merck Carbapenem Drugs Sales by Geographic Area in 2024
11.5.8 Merck Carbapenem Drugs SWOT Analysis
11.5.9 Merck Recent Developments
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Carbapenem Drugs Product Models, Descriptions and Specifications
11.6.4 Sun Pharmaceutical Industries Ltd. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.7 JW Pharmaceutical
11.7.1 JW Pharmaceutical Corporation Information
11.7.2 JW Pharmaceutical Business Overview
11.7.3 JW Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.7.4 JW Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 JW Pharmaceutical Recent Developments
11.8 Zhengde Pharmaceutical
11.8.1 Zhengde Pharmaceutical Corporation Information
11.8.2 Zhengde Pharmaceutical Business Overview
11.8.3 Zhengde Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.8.4 Zhengde Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Zhengde Pharmaceutical Recent Developments
11.9 Hospira Inc.
11.9.1 Hospira Inc. Corporation Information
11.9.2 Hospira Inc. Business Overview
11.9.3 Hospira Inc. Carbapenem Drugs Product Models, Descriptions and Specifications
11.9.4 Hospira Inc. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Hospira Inc. Recent Developments
11.10 WG Critical Care
11.10.1 WG Critical Care Corporation Information
11.10.2 WG Critical Care Business Overview
11.10.3 WG Critical Care Carbapenem Drugs Product Models, Descriptions and Specifications
11.10.4 WG Critical Care Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 WG Critical Care Recent Developments
11.11 Hanhui Pharmaceutical
11.11.1 Hanhui Pharmaceutical Corporation Information
11.11.2 Hanhui Pharmaceutical Business Overview
11.11.3 Hanhui Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.11.4 Hanhui Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hanhui Pharmaceutical Recent Developments
11.12 Zhuhai United Laboratories
11.12.1 Zhuhai United Laboratories Corporation Information
11.12.2 Zhuhai United Laboratories Business Overview
11.12.3 Zhuhai United Laboratories Carbapenem Drugs Product Models, Descriptions and Specifications
11.12.4 Zhuhai United Laboratories Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Zhuhai United Laboratories Recent Developments
11.13 ACS Dobfar S.p.A
11.13.1 ACS Dobfar S.p.A Corporation Information
11.13.2 ACS Dobfar S.p.A Business Overview
11.13.3 ACS Dobfar S.p.A Carbapenem Drugs Product Models, Descriptions and Specifications
11.13.4 ACS Dobfar S.p.A Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 ACS Dobfar S.p.A Recent Developments
11.14 Iterum Therapeutics plc (ITRM)
11.14.1 Iterum Therapeutics plc (ITRM) Corporation Information
11.14.2 Iterum Therapeutics plc (ITRM) Business Overview
11.14.3 Iterum Therapeutics plc (ITRM) Carbapenem Drugs Product Models, Descriptions and Specifications
11.14.4 Iterum Therapeutics plc (ITRM) Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Iterum Therapeutics plc (ITRM) Recent Developments
11.15 Daewoong Pharmaceutical
11.15.1 Daewoong Pharmaceutical Corporation Information
11.15.2 Daewoong Pharmaceutical Business Overview
11.15.3 Daewoong Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.15.4 Daewoong Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Daewoong Pharmaceutical Recent Developments
11.16 Aurobindo Pharma Ltd
11.16.1 Aurobindo Pharma Ltd Corporation Information
11.16.2 Aurobindo Pharma Ltd Business Overview
11.16.3 Aurobindo Pharma Ltd Carbapenem Drugs Product Models, Descriptions and Specifications
11.16.4 Aurobindo Pharma Ltd Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Aurobindo Pharma Ltd Recent Developments
11.17 Sumitomo Pharma
11.17.1 Sumitomo Pharma Corporation Information
11.17.2 Sumitomo Pharma Business Overview
11.17.3 Sumitomo Pharma Carbapenem Drugs Product Models, Descriptions and Specifications
11.17.4 Sumitomo Pharma Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Sumitomo Pharma Recent Developments
11.18 Pfizer Inc.
11.18.1 Pfizer Inc. Corporation Information
11.18.2 Pfizer Inc. Business Overview
11.18.3 Pfizer Inc. Carbapenem Drugs Product Models, Descriptions and Specifications
11.18.4 Pfizer Inc. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Pfizer Inc. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Carbapenem Drugs Industry Chain
12.2 Carbapenem Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Carbapenem Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Carbapenem Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Carbapenem Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Carbapenem Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Carbapenem Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Carbapenem Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Doripenem
1.2.3 Ertapenem
1.2.4 Imipenem
1.2.5 Meropenem
1.2.6 Panipenem
1.2.7 Biapenem
1.3 Market Segmentation by Application
1.3.1 Global Carbapenem Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Carbapenem Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Carbapenem Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Carbapenem Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Carbapenem Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Carbapenem Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Carbapenem Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Doripenem Market Size by Manufacturers
3.5.2 Ertapenem Market Size by Manufacturers
3.5.3 Imipenem Market Size by Manufacturers
3.5.4 Meropenem Market Size by Manufacturers
3.5.5 Panipenem Market Size by Manufacturers
3.5.6 Biapenem Market Size by Manufacturers
3.6 Global Carbapenem Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Carbapenem Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Carbapenem Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Carbapenem Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Carbapenem Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Carbapenem Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Carbapenem Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Carbapenem Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Carbapenem Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Carbapenem Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Carbapenem Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Carbapenem Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Carbapenem Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Carbapenem Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Carbapenem Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Carbapenem Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Carbapenem Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Carbapenem Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Carbapenem Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Carbapenem Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Shandong New Era Pharmaceutical
11.1.1 Shandong New Era Pharmaceutical Corporation Information
11.1.2 Shandong New Era Pharmaceutical Business Overview
11.1.3 Shandong New Era Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.1.4 Shandong New Era Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.1.6 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.1.7 Shandong New Era Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.1.8 Shandong New Era Pharmaceutical Carbapenem Drugs SWOT Analysis
11.1.9 Shandong New Era Pharmaceutical Recent Developments
11.2 Shenzhen Haibin Pharmaceutical
11.2.1 Shenzhen Haibin Pharmaceutical Corporation Information
11.2.2 Shenzhen Haibin Pharmaceutical Business Overview
11.2.3 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.2.4 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.2.6 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.2.7 Shenzhen Haibin Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.2.8 Shenzhen Haibin Pharmaceutical Carbapenem Drugs SWOT Analysis
11.2.9 Shenzhen Haibin Pharmaceutical Recent Developments
11.3 Sinopharm Guorui Pharmaceutical
11.3.1 Sinopharm Guorui Pharmaceutical Corporation Information
11.3.2 Sinopharm Guorui Pharmaceutical Business Overview
11.3.3 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.3.4 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Product in 2024
11.3.6 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Application in 2024
11.3.7 Sinopharm Guorui Pharmaceutical Carbapenem Drugs Sales by Geographic Area in 2024
11.3.8 Sinopharm Guorui Pharmaceutical Carbapenem Drugs SWOT Analysis
11.3.9 Sinopharm Guorui Pharmaceutical Recent Developments
11.4 Taiwan Biotech Co., Ltd.
11.4.1 Taiwan Biotech Co., Ltd. Corporation Information
11.4.2 Taiwan Biotech Co., Ltd. Business Overview
11.4.3 Taiwan Biotech Co., Ltd. Carbapenem Drugs Product Models, Descriptions and Specifications
11.4.4 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Product in 2024
11.4.6 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Application in 2024
11.4.7 Taiwan Biotech Co., Ltd. Carbapenem Drugs Sales by Geographic Area in 2024
11.4.8 Taiwan Biotech Co., Ltd. Carbapenem Drugs SWOT Analysis
11.4.9 Taiwan Biotech Co., Ltd. Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Carbapenem Drugs Product Models, Descriptions and Specifications
11.5.4 Merck Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Merck Carbapenem Drugs Sales by Product in 2024
11.5.6 Merck Carbapenem Drugs Sales by Application in 2024
11.5.7 Merck Carbapenem Drugs Sales by Geographic Area in 2024
11.5.8 Merck Carbapenem Drugs SWOT Analysis
11.5.9 Merck Recent Developments
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Carbapenem Drugs Product Models, Descriptions and Specifications
11.6.4 Sun Pharmaceutical Industries Ltd. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.7 JW Pharmaceutical
11.7.1 JW Pharmaceutical Corporation Information
11.7.2 JW Pharmaceutical Business Overview
11.7.3 JW Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.7.4 JW Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 JW Pharmaceutical Recent Developments
11.8 Zhengde Pharmaceutical
11.8.1 Zhengde Pharmaceutical Corporation Information
11.8.2 Zhengde Pharmaceutical Business Overview
11.8.3 Zhengde Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.8.4 Zhengde Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Zhengde Pharmaceutical Recent Developments
11.9 Hospira Inc.
11.9.1 Hospira Inc. Corporation Information
11.9.2 Hospira Inc. Business Overview
11.9.3 Hospira Inc. Carbapenem Drugs Product Models, Descriptions and Specifications
11.9.4 Hospira Inc. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Hospira Inc. Recent Developments
11.10 WG Critical Care
11.10.1 WG Critical Care Corporation Information
11.10.2 WG Critical Care Business Overview
11.10.3 WG Critical Care Carbapenem Drugs Product Models, Descriptions and Specifications
11.10.4 WG Critical Care Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 WG Critical Care Recent Developments
11.11 Hanhui Pharmaceutical
11.11.1 Hanhui Pharmaceutical Corporation Information
11.11.2 Hanhui Pharmaceutical Business Overview
11.11.3 Hanhui Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.11.4 Hanhui Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hanhui Pharmaceutical Recent Developments
11.12 Zhuhai United Laboratories
11.12.1 Zhuhai United Laboratories Corporation Information
11.12.2 Zhuhai United Laboratories Business Overview
11.12.3 Zhuhai United Laboratories Carbapenem Drugs Product Models, Descriptions and Specifications
11.12.4 Zhuhai United Laboratories Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Zhuhai United Laboratories Recent Developments
11.13 ACS Dobfar S.p.A
11.13.1 ACS Dobfar S.p.A Corporation Information
11.13.2 ACS Dobfar S.p.A Business Overview
11.13.3 ACS Dobfar S.p.A Carbapenem Drugs Product Models, Descriptions and Specifications
11.13.4 ACS Dobfar S.p.A Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 ACS Dobfar S.p.A Recent Developments
11.14 Iterum Therapeutics plc (ITRM)
11.14.1 Iterum Therapeutics plc (ITRM) Corporation Information
11.14.2 Iterum Therapeutics plc (ITRM) Business Overview
11.14.3 Iterum Therapeutics plc (ITRM) Carbapenem Drugs Product Models, Descriptions and Specifications
11.14.4 Iterum Therapeutics plc (ITRM) Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Iterum Therapeutics plc (ITRM) Recent Developments
11.15 Daewoong Pharmaceutical
11.15.1 Daewoong Pharmaceutical Corporation Information
11.15.2 Daewoong Pharmaceutical Business Overview
11.15.3 Daewoong Pharmaceutical Carbapenem Drugs Product Models, Descriptions and Specifications
11.15.4 Daewoong Pharmaceutical Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Daewoong Pharmaceutical Recent Developments
11.16 Aurobindo Pharma Ltd
11.16.1 Aurobindo Pharma Ltd Corporation Information
11.16.2 Aurobindo Pharma Ltd Business Overview
11.16.3 Aurobindo Pharma Ltd Carbapenem Drugs Product Models, Descriptions and Specifications
11.16.4 Aurobindo Pharma Ltd Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Aurobindo Pharma Ltd Recent Developments
11.17 Sumitomo Pharma
11.17.1 Sumitomo Pharma Corporation Information
11.17.2 Sumitomo Pharma Business Overview
11.17.3 Sumitomo Pharma Carbapenem Drugs Product Models, Descriptions and Specifications
11.17.4 Sumitomo Pharma Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Sumitomo Pharma Recent Developments
11.18 Pfizer Inc.
11.18.1 Pfizer Inc. Corporation Information
11.18.2 Pfizer Inc. Business Overview
11.18.3 Pfizer Inc. Carbapenem Drugs Product Models, Descriptions and Specifications
11.18.4 Pfizer Inc. Carbapenem Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Pfizer Inc. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Carbapenem Drugs Industry Chain
12.2 Carbapenem Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Carbapenem Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Carbapenem Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Carbapenem Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Carbapenem Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Carbapenem Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Carbapenem Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Carbapenem Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Carbapenem Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Carbapenem Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Carbapenem Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Carbapenem Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Carbapenem Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Carbapenem Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Carbapenem Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Carbapenem Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Carbapenem Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carbapenem Drugs as of 2024)
Table 16. Global Carbapenem Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Carbapenem Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Carbapenem Drugs Manufacturing Base and Headquarters
Table 19. Global Carbapenem Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Carbapenem Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Carbapenem Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Carbapenem Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Carbapenem Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Carbapenem Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Carbapenem Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Carbapenem Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Carbapenem Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Carbapenem Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Carbapenem Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Carbapenem Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Carbapenem Drugs Growth Accelerators and Market Barriers
Table 37. North America Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Carbapenem Drugs Growth Accelerators and Market Barriers
Table 40. Europe Carbapenem Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Carbapenem Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Carbapenem Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Carbapenem Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Shandong New Era Pharmaceutical Corporation Information
Table 51. Shandong New Era Pharmaceutical Description and Major Businesses
Table 52. Shandong New Era Pharmaceutical Product Models, Descriptions and Specifications
Table 53. Shandong New Era Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Shandong New Era Pharmaceutical Sales Value Proportion by Product in 2024
Table 55. Shandong New Era Pharmaceutical Sales Value Proportion by Application in 2024
Table 56. Shandong New Era Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 57. Shandong New Era Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 58. Shandong New Era Pharmaceutical Recent Developments
Table 59. Shenzhen Haibin Pharmaceutical Corporation Information
Table 60. Shenzhen Haibin Pharmaceutical Description and Major Businesses
Table 61. Shenzhen Haibin Pharmaceutical Product Models, Descriptions and Specifications
Table 62. Shenzhen Haibin Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Product in 2024
Table 64. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Application in 2024
Table 65. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 66. Shenzhen Haibin Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 67. Shenzhen Haibin Pharmaceutical Recent Developments
Table 68. Sinopharm Guorui Pharmaceutical Corporation Information
Table 69. Sinopharm Guorui Pharmaceutical Description and Major Businesses
Table 70. Sinopharm Guorui Pharmaceutical Product Models, Descriptions and Specifications
Table 71. Sinopharm Guorui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Product in 2024
Table 73. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Application in 2024
Table 74. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 75. Sinopharm Guorui Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 76. Sinopharm Guorui Pharmaceutical Recent Developments
Table 77. Taiwan Biotech Co., Ltd. Corporation Information
Table 78. Taiwan Biotech Co., Ltd. Description and Major Businesses
Table 79. Taiwan Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 80. Taiwan Biotech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Taiwan Biotech Co., Ltd. Sales Value Proportion by Product in 2024
Table 82. Taiwan Biotech Co., Ltd. Sales Value Proportion by Application in 2024
Table 83. Taiwan Biotech Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 84. Taiwan Biotech Co., Ltd. Carbapenem Drugs SWOT Analysis
Table 85. Taiwan Biotech Co., Ltd. Recent Developments
Table 86. Merck Corporation Information
Table 87. Merck Description and Major Businesses
Table 88. Merck Product Models, Descriptions and Specifications
Table 89. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Merck Sales Value Proportion by Product in 2024
Table 91. Merck Sales Value Proportion by Application in 2024
Table 92. Merck Sales Value Proportion by Geographic Area in 2024
Table 93. Merck Carbapenem Drugs SWOT Analysis
Table 94. Merck Recent Developments
Table 95. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 96. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 97. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 98. Sun Pharmaceutical Industries Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 100. JW Pharmaceutical Corporation Information
Table 101. JW Pharmaceutical Description and Major Businesses
Table 102. JW Pharmaceutical Product Models, Descriptions and Specifications
Table 103. JW Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. JW Pharmaceutical Recent Developments
Table 105. Zhengde Pharmaceutical Corporation Information
Table 106. Zhengde Pharmaceutical Description and Major Businesses
Table 107. Zhengde Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Zhengde Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Zhengde Pharmaceutical Recent Developments
Table 110. Hospira Inc. Corporation Information
Table 111. Hospira Inc. Description and Major Businesses
Table 112. Hospira Inc. Product Models, Descriptions and Specifications
Table 113. Hospira Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Hospira Inc. Recent Developments
Table 115. WG Critical Care Corporation Information
Table 116. WG Critical Care Description and Major Businesses
Table 117. WG Critical Care Product Models, Descriptions and Specifications
Table 118. WG Critical Care Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. WG Critical Care Recent Developments
Table 120. Hanhui Pharmaceutical Corporation Information
Table 121. Hanhui Pharmaceutical Description and Major Businesses
Table 122. Hanhui Pharmaceutical Product Models, Descriptions and Specifications
Table 123. Hanhui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hanhui Pharmaceutical Recent Developments
Table 125. Zhuhai United Laboratories Corporation Information
Table 126. Zhuhai United Laboratories Description and Major Businesses
Table 127. Zhuhai United Laboratories Product Models, Descriptions and Specifications
Table 128. Zhuhai United Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Zhuhai United Laboratories Recent Developments
Table 130. ACS Dobfar S.p.A Corporation Information
Table 131. ACS Dobfar S.p.A Description and Major Businesses
Table 132. ACS Dobfar S.p.A Product Models, Descriptions and Specifications
Table 133. ACS Dobfar S.p.A Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. ACS Dobfar S.p.A Recent Developments
Table 135. Iterum Therapeutics plc (ITRM) Corporation Information
Table 136. Iterum Therapeutics plc (ITRM) Description and Major Businesses
Table 137. Iterum Therapeutics plc (ITRM) Product Models, Descriptions and Specifications
Table 138. Iterum Therapeutics plc (ITRM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Iterum Therapeutics plc (ITRM) Recent Developments
Table 140. Daewoong Pharmaceutical Corporation Information
Table 141. Daewoong Pharmaceutical Description and Major Businesses
Table 142. Daewoong Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Daewoong Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Daewoong Pharmaceutical Recent Developments
Table 145. Aurobindo Pharma Ltd Corporation Information
Table 146. Aurobindo Pharma Ltd Description and Major Businesses
Table 147. Aurobindo Pharma Ltd Product Models, Descriptions and Specifications
Table 148. Aurobindo Pharma Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Aurobindo Pharma Ltd Recent Developments
Table 150. Sumitomo Pharma Corporation Information
Table 151. Sumitomo Pharma Description and Major Businesses
Table 152. Sumitomo Pharma Product Models, Descriptions and Specifications
Table 153. Sumitomo Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Sumitomo Pharma Recent Developments
Table 155. Pfizer Inc. Corporation Information
Table 156. Pfizer Inc. Description and Major Businesses
Table 157. Pfizer Inc. Product Models, Descriptions and Specifications
Table 158. Pfizer Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Pfizer Inc. Recent Developments
Table 160. Key Raw Materials Distribution
Table 161. Raw Materials Key Suppliers
Table 162. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 163. Milestones in Production Technology Evolution
Table 164. Distributors List
Table 165. Market Trends and Market Evolution
Table 166. Market Drivers and Opportunities
Table 167. Market Challenges, Risks, and Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Carbapenem Drugs Product Picture
Figure 2. Global Carbapenem Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Doripenem Product Picture
Figure 4. Ertapenem Product Picture
Figure 5. Imipenem Product Picture
Figure 6. Meropenem Product Picture
Figure 7. Panipenem Product Picture
Figure 8. Biapenem Product Picture
Figure 9. Global Carbapenem Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Carbapenem Drugs Report Years Considered
Figure 14. Global Carbapenem Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 16. Global Carbapenem Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Carbapenem Drugs Revenue Market Share by Region (2020-2031)
Figure 18. Global Carbapenem Drugs Sales (2020-2031) & (K Units)
Figure 19. Global Carbapenem Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Carbapenem Drugs Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Carbapenem Drugs Sales Volume Market Share in 2024
Figure 22. Global Carbapenem Drugs Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Doripenem Revenue Market Share by Manufacturer in 2024
Figure 25. Ertapenem Revenue Market Share by Manufacturer in 2024
Figure 26. Imipenem Revenue Market Share by Manufacturer in 2024
Figure 27. Meropenem Revenue Market Share by Manufacturer in 2024
Figure 28. Panipenem Revenue Market Share by Manufacturer in 2024
Figure 29. Biapenem Revenue Market Share by Manufacturer in 2024
Figure 30. Global Carbapenem Drugs Sales Market Share by Type (2020-2031)
Figure 31. Global Carbapenem Drugs Revenue Market Share by Type (2020-2031)
Figure 32. Global Carbapenem Drugs Sales Market Share by Application (2020-2031)
Figure 33. Global Carbapenem Drugs Revenue Market Share by Application (2020-2031)
Figure 34. North America Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 35. North America Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 37. North America Carbapenem Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 47. Europe Carbapenem Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. France Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Carbapenem Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 67. India Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Carbapenem Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Carbapenem Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 88. Carbapenem Drugs Industry Chain Mapping
Figure 89. Regional Carbapenem Drugs Manufacturing Base Distribution (%)
Figure 90. Global Carbapenem Drugs Production Market Share by Region (2020-2031)
Figure 91. Carbapenem Drugs Production Process
Figure 92. Regional Carbapenem Drugs Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Table 1. Global Carbapenem Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Carbapenem Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Carbapenem Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Carbapenem Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Carbapenem Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Carbapenem Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Carbapenem Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Carbapenem Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Carbapenem Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Carbapenem Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Carbapenem Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Carbapenem Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carbapenem Drugs as of 2024)
Table 16. Global Carbapenem Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Carbapenem Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Carbapenem Drugs Manufacturing Base and Headquarters
Table 19. Global Carbapenem Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Carbapenem Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Carbapenem Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Carbapenem Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Carbapenem Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Carbapenem Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Carbapenem Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Carbapenem Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Carbapenem Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Carbapenem Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Carbapenem Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Carbapenem Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Carbapenem Drugs Growth Accelerators and Market Barriers
Table 37. North America Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Carbapenem Drugs Growth Accelerators and Market Barriers
Table 40. Europe Carbapenem Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Carbapenem Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Carbapenem Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Carbapenem Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Carbapenem Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Carbapenem Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Carbapenem Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Shandong New Era Pharmaceutical Corporation Information
Table 51. Shandong New Era Pharmaceutical Description and Major Businesses
Table 52. Shandong New Era Pharmaceutical Product Models, Descriptions and Specifications
Table 53. Shandong New Era Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Shandong New Era Pharmaceutical Sales Value Proportion by Product in 2024
Table 55. Shandong New Era Pharmaceutical Sales Value Proportion by Application in 2024
Table 56. Shandong New Era Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 57. Shandong New Era Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 58. Shandong New Era Pharmaceutical Recent Developments
Table 59. Shenzhen Haibin Pharmaceutical Corporation Information
Table 60. Shenzhen Haibin Pharmaceutical Description and Major Businesses
Table 61. Shenzhen Haibin Pharmaceutical Product Models, Descriptions and Specifications
Table 62. Shenzhen Haibin Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Product in 2024
Table 64. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Application in 2024
Table 65. Shenzhen Haibin Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 66. Shenzhen Haibin Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 67. Shenzhen Haibin Pharmaceutical Recent Developments
Table 68. Sinopharm Guorui Pharmaceutical Corporation Information
Table 69. Sinopharm Guorui Pharmaceutical Description and Major Businesses
Table 70. Sinopharm Guorui Pharmaceutical Product Models, Descriptions and Specifications
Table 71. Sinopharm Guorui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Product in 2024
Table 73. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Application in 2024
Table 74. Sinopharm Guorui Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 75. Sinopharm Guorui Pharmaceutical Carbapenem Drugs SWOT Analysis
Table 76. Sinopharm Guorui Pharmaceutical Recent Developments
Table 77. Taiwan Biotech Co., Ltd. Corporation Information
Table 78. Taiwan Biotech Co., Ltd. Description and Major Businesses
Table 79. Taiwan Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 80. Taiwan Biotech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Taiwan Biotech Co., Ltd. Sales Value Proportion by Product in 2024
Table 82. Taiwan Biotech Co., Ltd. Sales Value Proportion by Application in 2024
Table 83. Taiwan Biotech Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 84. Taiwan Biotech Co., Ltd. Carbapenem Drugs SWOT Analysis
Table 85. Taiwan Biotech Co., Ltd. Recent Developments
Table 86. Merck Corporation Information
Table 87. Merck Description and Major Businesses
Table 88. Merck Product Models, Descriptions and Specifications
Table 89. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Merck Sales Value Proportion by Product in 2024
Table 91. Merck Sales Value Proportion by Application in 2024
Table 92. Merck Sales Value Proportion by Geographic Area in 2024
Table 93. Merck Carbapenem Drugs SWOT Analysis
Table 94. Merck Recent Developments
Table 95. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 96. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 97. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 98. Sun Pharmaceutical Industries Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 100. JW Pharmaceutical Corporation Information
Table 101. JW Pharmaceutical Description and Major Businesses
Table 102. JW Pharmaceutical Product Models, Descriptions and Specifications
Table 103. JW Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. JW Pharmaceutical Recent Developments
Table 105. Zhengde Pharmaceutical Corporation Information
Table 106. Zhengde Pharmaceutical Description and Major Businesses
Table 107. Zhengde Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Zhengde Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Zhengde Pharmaceutical Recent Developments
Table 110. Hospira Inc. Corporation Information
Table 111. Hospira Inc. Description and Major Businesses
Table 112. Hospira Inc. Product Models, Descriptions and Specifications
Table 113. Hospira Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Hospira Inc. Recent Developments
Table 115. WG Critical Care Corporation Information
Table 116. WG Critical Care Description and Major Businesses
Table 117. WG Critical Care Product Models, Descriptions and Specifications
Table 118. WG Critical Care Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. WG Critical Care Recent Developments
Table 120. Hanhui Pharmaceutical Corporation Information
Table 121. Hanhui Pharmaceutical Description and Major Businesses
Table 122. Hanhui Pharmaceutical Product Models, Descriptions and Specifications
Table 123. Hanhui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hanhui Pharmaceutical Recent Developments
Table 125. Zhuhai United Laboratories Corporation Information
Table 126. Zhuhai United Laboratories Description and Major Businesses
Table 127. Zhuhai United Laboratories Product Models, Descriptions and Specifications
Table 128. Zhuhai United Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Zhuhai United Laboratories Recent Developments
Table 130. ACS Dobfar S.p.A Corporation Information
Table 131. ACS Dobfar S.p.A Description and Major Businesses
Table 132. ACS Dobfar S.p.A Product Models, Descriptions and Specifications
Table 133. ACS Dobfar S.p.A Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. ACS Dobfar S.p.A Recent Developments
Table 135. Iterum Therapeutics plc (ITRM) Corporation Information
Table 136. Iterum Therapeutics plc (ITRM) Description and Major Businesses
Table 137. Iterum Therapeutics plc (ITRM) Product Models, Descriptions and Specifications
Table 138. Iterum Therapeutics plc (ITRM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Iterum Therapeutics plc (ITRM) Recent Developments
Table 140. Daewoong Pharmaceutical Corporation Information
Table 141. Daewoong Pharmaceutical Description and Major Businesses
Table 142. Daewoong Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Daewoong Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Daewoong Pharmaceutical Recent Developments
Table 145. Aurobindo Pharma Ltd Corporation Information
Table 146. Aurobindo Pharma Ltd Description and Major Businesses
Table 147. Aurobindo Pharma Ltd Product Models, Descriptions and Specifications
Table 148. Aurobindo Pharma Ltd Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Aurobindo Pharma Ltd Recent Developments
Table 150. Sumitomo Pharma Corporation Information
Table 151. Sumitomo Pharma Description and Major Businesses
Table 152. Sumitomo Pharma Product Models, Descriptions and Specifications
Table 153. Sumitomo Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Sumitomo Pharma Recent Developments
Table 155. Pfizer Inc. Corporation Information
Table 156. Pfizer Inc. Description and Major Businesses
Table 157. Pfizer Inc. Product Models, Descriptions and Specifications
Table 158. Pfizer Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Pfizer Inc. Recent Developments
Table 160. Key Raw Materials Distribution
Table 161. Raw Materials Key Suppliers
Table 162. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 163. Milestones in Production Technology Evolution
Table 164. Distributors List
Table 165. Market Trends and Market Evolution
Table 166. Market Drivers and Opportunities
Table 167. Market Challenges, Risks, and Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Carbapenem Drugs Product Picture
Figure 2. Global Carbapenem Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Doripenem Product Picture
Figure 4. Ertapenem Product Picture
Figure 5. Imipenem Product Picture
Figure 6. Meropenem Product Picture
Figure 7. Panipenem Product Picture
Figure 8. Biapenem Product Picture
Figure 9. Global Carbapenem Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Carbapenem Drugs Report Years Considered
Figure 14. Global Carbapenem Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 16. Global Carbapenem Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Carbapenem Drugs Revenue Market Share by Region (2020-2031)
Figure 18. Global Carbapenem Drugs Sales (2020-2031) & (K Units)
Figure 19. Global Carbapenem Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Carbapenem Drugs Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Carbapenem Drugs Sales Volume Market Share in 2024
Figure 22. Global Carbapenem Drugs Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Doripenem Revenue Market Share by Manufacturer in 2024
Figure 25. Ertapenem Revenue Market Share by Manufacturer in 2024
Figure 26. Imipenem Revenue Market Share by Manufacturer in 2024
Figure 27. Meropenem Revenue Market Share by Manufacturer in 2024
Figure 28. Panipenem Revenue Market Share by Manufacturer in 2024
Figure 29. Biapenem Revenue Market Share by Manufacturer in 2024
Figure 30. Global Carbapenem Drugs Sales Market Share by Type (2020-2031)
Figure 31. Global Carbapenem Drugs Revenue Market Share by Type (2020-2031)
Figure 32. Global Carbapenem Drugs Sales Market Share by Application (2020-2031)
Figure 33. Global Carbapenem Drugs Revenue Market Share by Application (2020-2031)
Figure 34. North America Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 35. North America Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 37. North America Carbapenem Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 47. Europe Carbapenem Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. France Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Carbapenem Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 67. India Carbapenem Drugs Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Carbapenem Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Carbapenem Drugs Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Carbapenem Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Carbapenem Drugs Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Carbapenem Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Carbapenem Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Carbapenem Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Carbapenem Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Carbapenem Drugs Revenue (2020-2025) & (US$ Million)
Figure 88. Carbapenem Drugs Industry Chain Mapping
Figure 89. Regional Carbapenem Drugs Manufacturing Base Distribution (%)
Figure 90. Global Carbapenem Drugs Production Market Share by Region (2020-2031)
Figure 91. Carbapenem Drugs Production Process
Figure 92. Regional Carbapenem Drugs Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232